An honest comparison
Semaglutide vs Tirzepatide
Semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have changed medical weight loss. Both are once-weekly injections that regulate appetite and blood sugar. Semaglutide activates the GLP-1 pathway; tirzepatide activates GLP-1 and GIP together, a dual mechanism that produced greater average weight loss in head-to-head-style trial comparisons.
The honest headline: the molecule matters less than the medicine around it. Dosing pace, side-effect management, nutrition, and muscle preservation determine whether the results are impressive and keepable, which is why RejuvLV runs this as provider-led care with Maria, not a subscription with a needle.
At a glance
Side by side
Swipe sideways to see all columns
| SemaglutideThe most established GLP-1, with years of cardiovascular and safety data behind it. | TirzepatideThe dual-agonist newcomer with the strongest average results in trials to date. | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist, slows gastric emptying and quiets appetite signaling | Dual GIP and GLP-1 agonist, appetite regulation plus improved insulin sensitivity |
| Average trial results | Around 15 percent body weight at higher doses in the STEP trials | Up to roughly 20 percent body weight at higher doses in the SURMOUNT trials |
| Dosing | Once weekly, titrated gradually over months | Once weekly, titrated gradually over months |
| Common side effects | Nausea, constipation, fatigue, strongest during dose increases | Similar GI profile, often reported as slightly milder at comparable stages |
| Best fit | Guests who value the longest track record, or respond well to GLP-1 alone | Guests with more weight to lose, insulin resistance, or a semaglutide plateau |
How we decide at RejuvLV
Precision over preference.
Trial averages are not a prescription. Maria weighs your health history, labs, medications, goals, and budget, then chooses the molecule and the pace. Some guests do beautifully on semaglutide and never need more, others plateau and are appropriate candidates to transition.
What we would leave out: crash dosing, unmonitored online scripts, and losing muscle along with fat. Our program pairs the medication with real supervision, nutrition guidance, and body-composition awareness, because the goal is not a number, it is a result you keep.
Questions
Frequently asked
On trial averages tirzepatide produced greater weight loss, roughly 20 percent versus 15 percent of body weight at the highest doses. Individually, response varies enough that better means the one your body tolerates and responds to under supervision, at a cost you can sustain.
The treatments discussed
Explore them at RejuvLV
Educational content, not medical advice. Every treatment decision at RejuvLV is made with Maria at consultation, based on your anatomy, history, and goals.